Table 3.
Incidence rate of MACE
| Study/Disease State | Exposure-adjusted incidence rate of MACE, n/PY (rate per 100 PY) | |||
|---|---|---|---|---|
| Ruxolitinib arm | Control arm | |||
| Control + crossover to ruxolitinib | Before or without crossover | After crossover to ruxolitinib | ||
| COMFORT-I (MF) | 7/460.4 (1.52) | 6/353.8 (1.70) | 1/98.9 (1.01) | 6/254.9 (2.35) |
| COMFORT-II (MF) | 7/409.5 (1.71) | 2/146.9 (1.36) | 1/67.2 (1.49) | 1/79.7 (1.25) |
| RESPONSE (PV) | 3/428.4 (0.70) | 4/404.6 (0.99) | 1/74.6 (1.34) | 3/329.9 (0.91) |
| RELIEF (PV) | 0/79.8 (0) | 2/91.6 (2.18) | 0/23.0 (0) | 2/68.5 (2.92) |
| Pooled population | 17/1378.1 (1.23) | 14/996.9 (1.40) | 3/263.8 (1.14) | 12/733.1 (1.64) |
MACE, major adverse cardiovascular event; MF, myelofibrosis; PV, polycythemia vera; PY, patient-year